Archive for the 'Medical Patents' Category
February 15th, 2011 by admin
A startling scientific breakthrough on Type 1 diabetes could help pave the way to a cure or perhaps significantly reduce the need for insulin therapy. A researcher at UT Southwestern, Dr. Roger Unger, reports in the February issue of Diabetes that by shutting down glucagon, a hormone that causes blood sugar to spike in patients with Type 1 diabetes, he was able to restore glucose tolerance to a normal level in mice. Even large doses of glucose failed to derail the therapeutic effect of the glucagon approach.
Continue reading ‘Diabetes Researcher May be ‘Close to a Cure’’
February 9th, 2011 by admin
India’s No.2 drugmaker Dr Reddy’s Laboratories Ltd said a U.S. district court has cleared the sale of its generic version of Sanofi-Aventis’ allergy medicine Allegra D24, sending its shares up nearly 4 percent. The U.S. District Court of New Jersey lifted an injunction passed last June against the Indian drugmaker from selling a copycat version of the drug, Dr Reddy’s said in a statement.
Continue reading ‘U.S. Court Clears Generic Allegra Sale’
February 1st, 2011 by admin
More drugmakers are seeing potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. The topic was at the forefront of plans discussed by several executives at this week’s JP Morgan healthcare conference in San Francisco. Kevin Sharer, chief executive officer at Amgen Inc, said the world’s largest maker of branded biotechnology drugs would consider entering the “biosimilars” space, particularly in emerging markets like Asia and South America.
Continue reading ‘Copying Biotech Medicine Attracts More Drugmakers’
December 31st, 2010 by admin
Novartis has submitted its meningococcal B vaccine Bexsero to the EU for marketing approval. “The Bexsero submission in the EU is an important milestone toward achieving the world’s first broad-coverage MenB vaccine through our unique multi-component approach,” said Andrin Oswald, head of Novartis Vaccines and Diagnostics Division. “Meningococcal disease is sudden and aggressive, leaving little time for treatment. Proactive vaccination of individuals has been shown to offer the best protection against fatal infectious diseases.
Continue reading ‘Novartis Files for Bexsero Approval’
December 30th, 2010 by admin
No, gold-plated liposomes are not a luxury gift that you’d find in your Christmas stocking, but they could someday give cancer patients the gift of life by selectively knocking out cancer cells while leaving healthy ones alone. This holiday gift comes courtesy of Marek Romanowski, an associate professor of biomedical engineering in the University of Arizona’s College of Engineering, along with the grad students in his lab, Xenia Kachur and Sarah Leung.
Continue reading ‘Gold-plated Liposomes an Anti-Cancer Stocking Stuffer’
December 6th, 2010 by admin
By Phase III, researchers are supposed to have a pretty good handle on just how promising an experimental therapy can be. There’s proof-of-concept data in the can and some clear indications of just how big a market a new drug can go on to capture.
Continue reading ‘The Top 10 Phase III Failures of 2010′
November 30th, 2010 by admin
The FDA has some of its biggest decisions of the year looming in the next few months. The first new lupus drug in half a century, a blood-thinner with mega-blockbuster potential, controversial weight drugs and more are all up for regulatory decisions that can move markets and either throw a bucket of cold water or high octane gasoline on stock prices.
Continue reading ‘FDA’s Top Q4 Blockbuster Drug Decisions’
November 2nd, 2010 by admin
The side effects of the standard medication for Parkinson’s disease have long been a preoccupation of brain researchers. Now Daniella Rylander has presented new findings in a recently defended PhD thesis at Lund University that provide hope of more effective medication for those who suffer from the nerve cell disease.
Continue reading ‘New Parkinson’s Drug Development’
October 29th, 2010 by admin
Allergan has done it. The FDA finally approved its wrinkle-fighter Botox as a treatment for migraines. The new indication could add $1 billion to its current annual sales of $1.3 billion, analysts say. “This is the most meaningful market expansion that the product has had since it was approved for cosmetic use,” Piper Jaffray’s David Amsellem tells Bloomberg.
Continue reading ‘New Migraine Use for Botox Could be Worth $1B’
October 14th, 2010 by admin
The Indian pharmaceutical industry has been shaken up lately, worried that multinational drugmakers will come in and completely take over their drug market. The fears aren’t unfounded; Big Pharma, after all, has been targeting the subcontinent as a key location for expansion, as sales-growth slows in the U.S. and Europe.
Continue reading ‘Pharma Protests Indian Licensing Proposal’
